Agios Pharmaceuticals, Inc. share price logo

Agios Pharmaceuticals, Inc. Share Price

NASDAQ: AGIO

Mid Cap

$32.88

-0.89

(-2.64%)

as on

Agios Pharmaceuticals, Inc. Stock Performance

as on April 10, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $32.59
    $33.53
    downward going graph

    0.88%

    Downside

    1.98%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $22.24
    $46.00
    downward going graph

    32.36%

    Downside

    39.90%

    Upside

    downward going graph

Agios Pharmaceuticals, Inc. share price movements today

Previous Close
$33.77
Open
$33.53
Volume
793.2K
Day's Low - High
$32.59 - $33.53
52 Week Low - High
$22.24 - $46.00

Agios Pharmaceuticals, Inc. Historical Returns

1 Month Return
+ 18.37 %
3 Month Return
+ 18.87 %
1 Year Return
+ 28.5 %
3 Year Return
+ 55.12 %
5 Year Return
-36.01 %

Agios Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators

Check Agios Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.1B

EPS (TTM)

-6.5063

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

1.63

Industry PE ratio

7.878053097345132

PEG Ratio

0

EBITDA

-467.0M

Revenue (TTM)

54.0M

Profit Margin

0.00%

Return On Equity TTM

-30.20%

Agios Pharmaceuticals, Inc. Stock Valuation

Track how Agios Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.

Agios Pharmaceuticals, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-7.40x)

December 31, 2024

Today (1.63x)

April 9, 2026

Industry (7.88x)

April 9, 2026

Highest (2.47x)

June 30, 2021

LowHigh

Today’s Price to Earnings Ratio: 1.63x

Agios Pharmaceuticals, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Agios Pharmaceuticals, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Agios Pharmaceuticals, Inc. image
Agios Pharmaceuticals, Inc.
BUY$2.1B-36.01%1.630.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$42.4B136.74%137.138.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$109.8B108.07%28.1732.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$34.9BNA124.015.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$80.4B63.21%18.3231.41%

Stock Returns calculator for Agios Pharmaceuticals, Inc. Stock including INR - Dollar returns

The Agios Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Agios Pharmaceuticals, Inc. investment value today

Current value as on today

₹1,33,743

Returns

₹33,743

(+33.74%)

Returns from Agios Pharmaceuticals, Inc. Stock

₹25,114 (+25.11%)

Dollar Impact

₹8,629 (+8.63%)

Analyst Recommendation on Agios Pharmaceuticals, Inc. Stock

Based on 15 analysts

BUY

73.33%

Buy

26.67%

Hold

0.00%

Sell

Based on 15 analysts, 73.33% of analysts recommend a 'BUY' rating for Agios Pharmaceuticals, Inc.. Average target price of $43.75

Agios Pharmaceuticals, Inc. Share Price Target

Get share price movements and forecasts by analysts on Agios Pharmaceuticals, Inc..

What analysts predicted

24.85%UPSIDE

Target Price

$43.75

Current Price

$32.88

Analyzed by

15 Analysts

Target

$43.75

Agios Pharmaceuticals, Inc. target price $43.75, a slight upside of 24.85% compared to current price of $32.88. According to 15 analysts rating.

Agios Pharmaceuticals, Inc. Stock’s Investor Sentiment and Interest

Search interest for Agios Pharmaceuticals, Inc. Stock has decreased by -11% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-11% versus previous 30 day period

Agios Pharmaceuticals, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
7
7
8
8
8
10
8
12
12
19
Gross Profit
6
5
6
5
8
9
7
9
11
19
Operating Income
-100
-106
-92
-105
-102
-125
-106
-127
-116
-121
EBITDA
-99
-104
-90
-104
-101
-123
-105
-110
-102
-120
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
1
1
1
1
1
1
1
1
1
1
Income Before Tax
-91
-95
-81
-96
1,001
-105
-89
-112
-103
-109
Income Tax Expense
-9
1
1
-
53
-8
-
-
-
-1
Net Income
-91
-95
-81
-96
947
-96
-89
-112
-103
-108
Net Profit Margin
-1234.27%
-1350.70%
-995.84%
-1115.71%
10574.69%
-899.56%
-1023.25%
-899.40%
-803.05%
-541.09%

Agios Pharmaceuticals, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
69
43
94
117
203
0
14
26
36
54
Gross Profit
69
43
92
116
-18
-18
12
17
32
47
Operating Income
-200
-320
-362
-426
-335
-378
-389
-391
-425
-472
EBITDA
-195
-314
-355
-394
-310
-337
-380
-384
-420
-466
Interest Expense
2
6
16
14
17
0
12
-
-
-
Depreciation
-
6
7
8
9
9
8
6
5
5
Income Before Tax
-198
-314
-346
-411
-329
-356
-231
-352
717
-413
Income Tax Expense
-5
-6
32
-14
7
-1,977
-157
6
44
-1
Net Income
-198
-314
-346
-411
-327
1,604
-231
-352
673
-412
Net Profit Margin
-283.97%
-731.60%
-366.61%
-348.97%
-161.11%
3875280.74%
-1627.82%
-1312.63%
1845.92%
-764.01%

Agios Pharmaceuticals, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-95
-81
-96
947
-96
-89
-112
-103
-108
Operating Cash Flow
-72
-99
-72
-84
-133
-111
-77
-88
-96
Investing Cash Flow
95
124
37
250
-49
112
78
95
90
Financing Cash Flow
0
5
1
2
4
1
0
4
2
Change in Cash
23
30
-34
169
-177
2
1
11
-3

Agios Pharmaceuticals, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-314
-346
-411
-329
-356
-231
-352
673
-412
Operating Cash Flow
-285
-304
-370
-290
-407
-309
-296
-389
-372
Investing Cash Flow
-57
-273
91
75
1,248
243
239
363
377
Financing Cash Flow
285
546
289
261
-765
2
5
14
8
Change in Cash
-58
-32
10
46
75
-63
-51
-11
12

Global Institutional Holdings in Agios Pharmaceuticals, Inc.

Funds
Holdings
Erste Asset Management GmbH
4.79%
Citadel Advisors Llc
1.86%
Geode Capital Management, LLC
2.41%
Deutsche Bank AG
1.58%
Macquarie Group Ltd
3.34%
See all

Agios Pharmaceuticals, Inc. News & Key Events

  • img

    Today's Timeline - 24 December

    Wed, 10:37 AM

    -

    Agios Pharmaceuticals announces FDA approval for AQVESME (mitapivat) for anemia in thalassemia, shares fell 1.4% to $24.59.

    Wed, 06:01 PM

    -

    Agios shares rise 9.80% to $27.00 premarket after FDA approval of AQVESME for thalassemia-related anemia.

    Wed, 06:48 PM

    -

    FDA expands approval for mitapivat, expected to generate $320 million additional peak revenue opportunity.

  • img

    Today's Timeline - 24 December

    Wed, 10:33 PM

    -

    Management outlines marketing plans for AQVESME, targeting 4,000 patients with a price of $425,000 annually.

Insights on Agios Pharmaceuticals, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 8.72M → 19.96M (in $), with an average increase of 22.9% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, AGIO stock has moved up by 19.5%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, AGIO has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Beone Medicines Ltd has given 49.9% return, outperforming this stock by 16.5%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -103.43M → -108.03M (in $), with an average decrease of 4.5% per quarter

About Agios Pharmaceuticals, Inc.

at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
OrganisationAgios Pharmaceuticals, Inc.
Headquarters88 Sidney Street, Cambridge, MA, United States, 02139
IndustryHealth Technology
CEOMr. Brian M. Goff M.B.A.
E-voting on sharesClick here to vote

Key Management of Agios Pharmaceuticals, Inc.

Name

Title

Mr. T. J. Washburn

VP, Controller & Principal Accounting Officer

Ms. Cecilia Jones

Chief Financial Officer

Mr. James William Burns

Corporate Secretary & Chief Legal Officer

Dr. Lewis clayton Cantley Ph.D.

Co-Founder

Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.

Co-Founder

Dr. Craig B. Thompson M.D.

Co-Founder

Dr. Shin-San Su Ph.D.

Co-Founder

Mr. Brian M. Goff M.B.A.

CEO & Director

Dr. Sarah Gheuens M.D., Ph.D.

Chief Medical Officer and Head of Research & Development

Ms. Tsveta Milanova

Chief Commercial Officer

FAQs

What is Agios Pharmaceuticals, Inc. share price today?

Agios Pharmaceuticals, Inc. share price today is $32.88 as on at the close of the market. Agios Pharmaceuticals, Inc. share today touched a day high of $33.53 and a low of $32.59.

What is the 52 week high and 52 week low for Agios Pharmaceuticals, Inc. share?

Agios Pharmaceuticals, Inc. share touched a 52 week high of $46 on and a 52 week low of $22.24 on . Agios Pharmaceuticals, Inc. stock price today i.e. is closed at $32.88,which is 28.52% down from its 52 week high and 47.84% up from its 52 week low.

What is Agios Pharmaceuticals, Inc.'s market capitalisation today?

Agios Pharmaceuticals, Inc. market capitalisation is $0.00T as on .

How to invest in Agios Pharmaceuticals, Inc. Stock (AGIO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Agios Pharmaceuticals, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Agios Pharmaceuticals, Inc. Shares that will get you 0.0456 shares as per Agios Pharmaceuticals, Inc. share price of $32.88 per share as on April 10, 2026 at 1:29 am IST.

What is the minimum amount required to buy Agios Pharmaceuticals, Inc. Stock (AGIO) from India?

Indian investors can start investing in Agios Pharmaceuticals, Inc. (AGIO) shares with as little as ₹92.637 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹926.37 in Agios Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Agios Pharmaceuticals, Inc. share’s latest price of $32.88 as on April 10, 2026 at 1:29 am IST, you will get 0.3041 shares of Agios Pharmaceuticals, Inc.. Learn more about fractional shares .

What are the returns that Agios Pharmaceuticals, Inc. has given to Indian investors in the last 5 years?

Agios Pharmaceuticals, Inc. stock has given -36.01% share price returns and 24.53% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?